La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Althea Group Holdings Résultats passés
Passé contrôle des critères 0/6
Althea Group Holdings's earnings have been declining at an average annual rate of -10%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 47.4% per year.
Informations clés
-10.0%
Taux de croissance des bénéfices
4.6%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 31.2% |
| Taux de croissance des recettes | 47.4% |
| Rendement des fonds propres | -138.4% |
| Marge nette | -73.2% |
| Dernière mise à jour des bénéfices | 31 Dec 2023 |
Mises à jour récentes des performances passées
Recent updates
Althea Group Holdings Limited's (ASX:AGH) Prospects Need A Boost To Lift Shares
Jun 08
Investors Continue Waiting On Sidelines For Althea Group Holdings Limited (ASX:AGH)
Feb 23Althea Group Holdings Limited (ASX:AGH) Shares Fly 28% But Investors Aren't Buying For Growth
Apr 18We Think Althea Group Holdings (ASX:AGH) Needs To Drive Business Growth Carefully
Jul 11The Consensus EPS Estimates For Althea Group Holdings Limited (ASX:AGH) Just Fell A Lot
Feb 28Is Althea Group Holdings (ASX:AGH) In A Good Position To Invest In Growth?
Feb 25When Will Althea Group Holdings Limited (ASX:AGH) Become Profitable?
Mar 13Can You Imagine How Althea Group Holdings' (ASX:AGH) Shareholders Feel About The 28% Share Price Increase?
Feb 06
What You Need To Know About Althea Group Holdings Limited's (ASX:AGH) Investor Composition
Dec 04Ventilation des recettes et des dépenses
Comment Althea Group Holdings gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 23 | 29 | -21 | 24 | 0 |
| 30 Sep 23 | 27 | -17 | 24 | 0 |
| 30 Jun 23 | 25 | -14 | 24 | 0 |
| 31 Mar 23 | 24 | -14 | 23 | 0 |
| 31 Dec 22 | 23 | -14 | 21 | 0 |
| 30 Sep 22 | 22 | -13 | 20 | 0 |
| 30 Jun 22 | 21 | -12 | 19 | 0 |
| 31 Mar 22 | 18 | -13 | 20 | 0 |
| 31 Dec 21 | 16 | -14 | 20 | 0 |
| 30 Sep 21 | 14 | -14 | 20 | 0 |
| 30 Jun 21 | 12 | -15 | 19 | 0 |
| 31 Mar 21 | 10 | -15 | 17 | 0 |
| 31 Dec 20 | 8 | -15 | 15 | 0 |
| 30 Sep 20 | 7 | -15 | 15 | 0 |
| 30 Jun 20 | 5 | -15 | 14 | 0 |
| 31 Mar 20 | 4 | -15 | 14 | 0 |
| 31 Dec 19 | 2 | -15 | 14 | 0 |
| 30 Sep 19 | 2 | -12 | 11 | 0 |
| 30 Jun 19 | 1 | -9 | 9 | 0 |
| 31 Dec 18 | 0 | -4 | 4 | 0 |
| 30 Sep 18 | 0 | -3 | 3 | 0 |
| 30 Jun 18 | 0 | -1 | 1 | 0 |
Des revenus de qualité: AGH is currently unprofitable.
Augmentation de la marge bénéficiaire: AGH is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: AGH is unprofitable, and losses have increased over the past 5 years at a rate of 10% per year.
Accélération de la croissance: Unable to compare AGH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: AGH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).
Rendement des fonds propres
ROE élevé: AGH has a negative Return on Equity (-138.38%), as it is currently unprofitable.